Structural details of monoclonal antibody m971 recognition of the membrane-proximal domain of CD22

June Ereño-Orbea 1,2, Xianglei Liu 3, Taylor Sicard 4, Iga Kucharska, Wei Li 1, Dorota Borovsky 1, Hong Cui 1, Yang Feng 1, Dimiter S. Dimitrov 3, and Jean-Philippe Julien 1,4,5, *

From the 1 Program in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada; 2 IKERBASQUE, Basque Foundation for Science, Bilbao, Bizkaia, Spain; 3 Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pennsylvania, USA; 4 Department of Biochemistry, 5 Department of Immunology, University of Toronto, Toronto, Ontario, Canada; 6 Protein Interactions Group, Center for Cancer Research Nanobiology Program, Center for Cancer Research, National Institutes of Health, Frederick, Maryland, USA

Edited by Peter Cresswell

Cluster of differentiation-22 (CD22) belongs to the sialic acid–binding immunoglobulin (Ig)-like lectin family of receptors that is expressed on the surface of B cells. It has been classified as an inhibitory coreceptor for the B-cell receptor because of its function in establishing a baseline level of B-cell inhibition. The restricted expression of CD22 on B cells has made it an attractive target for B-cell depletion in cases of B-cell malignancies. Genetically modified T cells with chimeric antigen receptors (CARs) derived from the m971 antibody have shown promise when used as an immunotherapeutic agent against B-cell acute lymphoblastic leukemia. A key aspect of the efficacy of this CAR-T was its ability to target a membrane-proximal epitope on the CD22 extracellular domain; however, the molecular details of m971 recognition of CD22 have thus far remained elusive. Here, we report the crystal structure of the m971 fragment antigen-binding complex in the two most membrane-proximal Ig-like domains of CD22 (CD22d6–d7). The m971 epitope on CD22 resides at the most proximal Ig domain (d7) to the membrane, and the antibody paratope contains electrostatic surfaces compatible with interactions with phospholipid head groups. Together, our data identify molecular details underlying the successful transformation of an antibody epitope on CD22 into an effective CAR immunotherapeutic target.

A rapidly expanding immunotherapy to treat hematological cancer uses ex vivo–modified mature T lymphocytes that are engineered to express chimeric antigen receptors (CARs) specific for a targeted antigen on cancer cells (1). The engineered CAR is capable of redirecting T cells (chimeric antigen receptor T cell [CAR-T cells]) to specifically target and destroy malignant cells expressing the antigen without major histocompatibility complex restriction (2, 3). In the case of B-cell malignancies, such as B cell–associated leukemias and lymphomas, CD19 is a compelling target for CAR-T cell–based therapies because of its restricted expression to the B-cell lineage, thus reducing off-target global cytotoxic effects. To date, there are two anti-CD19 CAR-T cells approved for use by the US Food and Drug Administration for the treatment of pediatric acute lymphoblastic leukemia and adult diffuse large B-cell lymphoma (4). Although complete tumor regression (70–90% for B-cell acute lymphoblastic leukemia [B-ALL]) can be achieved in a substantial fraction of patients, anti-CD19 CAR-T cell therapy has also suffered resistance in some cases because of the loss of expression of the antigen (5–8).

Cluster of differentiation-22 (CD22) represents an alternative target antigen for CAR-T cells in B-cell malignancies. Indeed, CAR-T cells targeting CD22 have shown potent antineoplastic effects in a phase 1 clinical trial enrolling patients who failed to achieve remission in the CD19 CAR-T cell therapy protocol (9, 10). CD22 is a transmembrane glycoprotein expressed on B cells that commonly retain expression in CD19neg tumors (9, 10). The canonical function of CD22 is to dampen the activating signal of the B-cell receptor. As part of the sialic acid–binding immunoglobulin (Ig)-like lectin (Siglec) family, the extracellular domain (ECD) of CD22 recognizes glycans terminated in α,2,6-sialic acid, and its binding site is located at the most membrane-distal domain (d1) (11). The CD22 ECD is composed of seven Ig-like domains (d1–d7) and contains 12 predicted N-linked glycans (Fig. 1). Binding to sialic acid results in phosphorylation of the CD22 intracellular tyrosine-based inhibitory motifs, subsequent recruitment of tyrosine-protein phosphatase SHP-1, and the dampening of the B-cell response (12). CD22 itself is covered with N-linked glycans terminated in α,2,6-sialic acid and forms homooligomers on the surface of B cells (13). The tilted conformation adopted by CD22 and the location of the binding site on d1 has been proposed to favor cis-interactions and the formation of these nanoclusters (11).

The essential components of a CAR include the extracellular antigen-binding domain, usually a single-chain fragment variable, a transmembrane, and hinge region that anchors the receptor on the cell surface and projects the single-chain fragment variable out to the ECD, and intracellular signaling motifs from the T-cell receptor (such as CD3ξ, CD28, 4-1BB, if any, are not mentioned in the text).
Molecular details of CD22 recognition by mAb m971

Proximal Ig domains d6 and d7 of CD22 (CD22<sub>d6–d7</sub>) and reveals that m971 binds at the membrane-most base of CD22 to mediate its antileukemic effects. Together, our data contribute molecular principles of antigen recognition underlying the development of potent CAR-T cells.

Results

Structure of CD22 d6–d7 domains

To delineate the m971 epitope at high resolution, we obtained crystals of the membrane-proximal domains d6 and d7 of the extracellular portion (ECD) of human CD22 (CD22<sub>d6–d7</sub>) in complex with the m971 fragment antigen-binding (Fab), which diffracted to 2.4 Å resolution (Table 1). The antigen–antibody structure was solved by molecular replacement using the m971 Fab as an initial search model, which was derived from its 1.6 Å resolution crystal structure in complex with the crystallization chaperone anti-kappa V<sub>λ</sub>H domain (15) (Table 1). The phases obtained were of sufficient quality for manual building of the d6 and d7 domains of CD22. CD22 d6 showed overall weaker electron density compared to d7, presumably because of lower crystal packing interactions and thus more flexibility in the crystal lattice.

As predicted from the primary sequence, the two consecutive CD22 d6 and d7 Ig domains possess a C2-type Ig fold, or OX40) that are triggered upon antigen engagement. Thus, CARs are designed to transduce antigen-recognition events into signaling cascades that evokes T-cell effector functions, such as the secretion of cytotoxic factors and proinflammatory cytokines. Previous studies on the development of anti-CD22 CAR-T cells showed the relevance of targeting a membrane-proximal epitope on CD22 ECD (10). Interestingly, almost all CD22-directed monoclonal antibodies (mAbs) reported to date recognize membrane-distal epitopes on CD22; for example, the epitope of epratuzumab was structurally delineated at the interface of the CD22 d2 and d3 domains (Fig. 1) (11). On the other hand, mAb m971 was previously shown to target a membrane-proximal epitope on CD22, and a CAR-T cell using the m971 binding specificity achieved superior antileukemic effects in preclinical models of B-ALL in comparison with anti-CD22 CAR-T cells of similar affinity targeting membrane-distal regions (10).

To provide molecular insights into antibody recognition that leads into the development of effective anti-CD22 CAR-T cells, we structurally and biophysically delineated the binding site of m971 on CD22 (14). Our crystal structure delineates the three-dimensional architecture of the most membrane-

Figure 1. Schematic representation of CD22 on the cell surface bound by therapeutic antibody epratuzumab. The extracellular domain (ECD) is comprised of seven Ig domains (d1–d7). CD22 is a membrane glycoprotein with 12 N-linked glycans (blue spheres) on the ECD. The CD22<sub>d6–d7</sub> construct (residues 505–688) contains domains d6 (in yellow) and d7 (in wheat), which are predicted to have two N-linked glycans on residues N574 and N634. Epratuzumab binds the CD22 d2/d3 interface close to N-linked glycan N231 (11). Ig, immunoglobulin.

Table 1

| Attributes                      | m971 Fab–V<sub>λ</sub>H complex | CD22<sub>d6–d7</sub>–m971 Fab complex |
|--------------------------------|----------------------------------|--------------------------------------|
| PDB ID                         | 7O4Y                             | 7O52                                 |
| Data collection statistics     |                                  |                                      |
| Wavelength (Å)                 | 0.97951                          | 1.03320                              |
| Resolution range (Å)           | 39.1–1.60                        | 48.87–2.41                           |
| Multiplicity                   | (1.66–1.60)                      | (2.49–2.41)                          |
| Space group                    | P<sub>3</sub>z                    |                                      |
| Unit cell a, b, c (Å)           | 73.9, 73.9, 98.8                 | 61.5, 119.7, 241.7                   |
| α, β, γ (°)                    | 90, 90, 120                      | 60, 90, 90                           |
| Total reflections              | 329,887                          | 461,724                              |
| Unique reflections             | 79,795 (12,852)                  | 35,031 (5468)                        |
| Completeness (%)               | 99.8 (99.4)                      | 99.5 (95.2)                          |
| Mean I/σ                       | 17.3 (2.3)                       | 20.2 (1.5)                           |
| Wilson B-factor (Å<sup>2</sup>) | 20.9                             | 60.4                                 |
| R<sub>merge</sub>              | 0.043 (0.436)                    | 0.087 (0.825)                        |
| R<sub>free</sub>               | 0.024 (0.249)                    | 0.025 (0.236)                        |
| CC<sub>1/2</sub>               | 99.9 (77.7)                      | 99.9 (58.4)                          |
| Refinement statistics          |                                  |                                      |
| Resolution (Å)                 | 39.1–1.60                        | 48.87–2.41                           |
| R<sub>work</sub>               | 0.176 (0.253)                    | 0.226 (0.349)                        |
| R<sub>free</sub>               | 0.208 (0.266)                    | 0.265 (0.407)                        |
| Number of nonhydrogen atoms    | 4932                             | 4746                                 |
| Macromolecules                 | 4227                             | 4652                                 |
| Heteroatoms                    | -                                | 57                                   |
| Solvent                        | 705                              | 37                                   |
| RMS (bonds)                    | 0.011 (0.002)                    |                                      |
| RMS (angles)                   | 1.42 (0.60)                      |                                      |
| Ramachandran statistics:       |                                  |                                      |
| Favorable (%)                  | 97.9                             | 95.9                                 |
| Allowed (%)                    | 2.0                              | 3.5                                  |
| Outliers (%)                   | 0                                | 0.5                                  |
| Rotamer outliers (%)           | 0.6                              | 0.0                                  |
| Average B (Å<sup>2</sup>)      | 25.6                             | 69.8                                 |
| Macromolecules                 | 25.6                             | 69.8                                 |
| Heteroatoms                    | -                                | 93.5                                 |
| Solvent                        | 34.6                             | 55.7                                 |
| Clashscore                     | 2.3                              | 3.8                                  |
each with one intradomain disulfide linkage (C529-C517 in d6 and C616-C659 in d7) (Fig. 2). In contrast, the most membrane-proximal domain of the related Siglec-4 (MAG) showed a C1-type fold and two intradomain disulfide linkages (Fig. S1)(16). Thus, the CD22_{d6–d7} structure highlights differences in the structures adopted by membrane-proximal Ig domains among the Siglec family. In the cocrystal structure, CD22 residues 574 to 580 located in d6 could not be built.
Molecular details of CD22 recognition by mAb m971

because of apparent high flexibility in this loop. Only one of the two predicted N-linked glycans in CD22_{d6-d7} was visible in the electron density and was built at N634 in d7, with one residual N-acetyllactosamine moiety left after endoglycosidase H deglycosylation of the recombinant CD22_{d6-d7} expressed in HEK 293 Gnt1−/− (HEK 293S) cells before crystallization (Fig. 2).

m971 Fab recognizes the CD22 d7 domain

The cocrystal structure revealed that the m971 Fab binds to the base of the CD22 d7 domain (Fig. 2). Comparison of the variable domain of the CD22-ligated and -unliganded crystal structures of m971 Fab indicated that its paratope is largely preconfigured for binding its epitope (RMSD of 0.33 Å) (Fig. S2). The three heavy-chain complementarity-determining regions (HCDRs 1, 2, and 3) and the light-chain complementarity-determining regions 1 and 2 of m971 interact with the C β-strand, and loops C–E and E–F of CD22 d7 (Fig. 3). The buried surface area on the antigen is extensive (990 Å²) and is primarily mediated by the heavy chain (722 Å²) and less by the light chain (268 Å²) (Table S1). As opposed to mAb epratuzumab, in which the epitope includes an N-linked glycan at position N231 on d2 (Fig. 1), m971 does not include the N-linked glycan on d7 (N634). This result was further corroborated by binding kinetics experiments with a KO of the N634 glycosylation site at d7 (N634A mutation), which resulted in a binding affinity similar to WT CD22 (Fig. 3). Together, our data indicate that m971 recognizes the closest ECD to the membrane of CD22 and that N-linked glycosylation on CD22 does not impact the ability to access its epitope.

A Y^{H52A} R mutation on m971 Fab increases affinity toward CD22 ECD

To probe the CD22–m971 binding interface, we next introduced single-point mutations by site-directed mutagenesis in the m971 Fab. Residues S^{H53} in HCDR2 and L^{H100} in HCDR3 were mutated in attempts to alter the affinity toward CD22 (Fig. 4). Interestingly, the m971 paratope contains a basic patch in HCDR2 (Fig. S2). Based on this observation, we decided to mutate Y^{H52A} to a basic (R) or acidic (E) residue in HCDR2 to determine the effect of gaining positive or negative charge at the interface between m971 and CD22 (Fig. 5). Measuring intrinsic fluorescence simultaneously with static light scattering (SLS) through a temperature ramp, we found that all mutants exhibited similar onset melting temperatures (T_{m}) and onset aggregation temperatures (T_{onset}), in comparison with WT m971, under three different buffer conditions (pH 5.6, 7.4, and 9) (Fig. S3).

In biolayer interferometry (BLI) experiments, the affinity of WT m971 to the full-length ECD of CD22 (CD22_{d1-d7}) was calculated to be in the low nanomolar range (25 nM; Fig. 4), which is comparable with the affinity previously measured for the IgG by flow cytometry (75 nM) (14). All m971 Fab mutants tested showed measurable binding to CD22_{d1-d7}. As expected from our structural studies, the S^{H53}A mutation in HCDR2 decreased the binding affinity of m971 Fab to CD22 by approximately 8-fold (K_{D} = 207 nM), primarily because of a faster off-rate (Fig. 4). Indeed, hydrogen bonds formed between m971 S^{H53} and CD22 D631 and N633 would be lost with an alanine mutation (Fig. 4). Similarly, substitution of the hydrophobic L for Q, a polar residue, at position 100 in the HCDR3 (H^{100}Q mutation) resulted in an ~4-fold decrease in binding affinity (K_{D} = 94 nM) to CD22_{d1-d7} (Fig. 4). Interestingly, while substitution of the aromatic Y^{H52A} residue for the negatively charged E residue in HCDR2 (Y^{H52E} mutation) minimally affected its binding affinity (K_{D} = 33 nM), substitution to positively charged R (Y^{H52A}R) increased the binding affinity ~5-fold to CD22_{d1-d7} (K_{D} = 5 nM). The observed increase in the affinity for Y^{H52A}R mutant results from a slower off-rate (Fig. 4). We further analyzed the activity of a CAR-T cell containing the
variant $\text{Y}^{\text{H52A}}$ (Fig. S4). However, the slight gain in affinity for CD22 did not result in increased cell killing. Together, we conclude that our mutagenesis data of the m971 paratope validates the CD22d6–d7-m971 Fab cocrystal structure.

**Anion-binding sites on the surface of the d7 domain of CD22**

Three strong spherical electron densities close to positively charged surfaces on the CD22 d7 domain were observed in the electron density map (Fig. S5). Based on their shape, size, and environment, a high concentration of ammonium sulfate in the crystallization buffer, we interpreted these densities as sulfate ions (SO$_4$ I, II, and III) (Fig. 5). The B-factors of the sulfate ions range from 87 to 108 Å$^2$, only slightly higher than the overall B-factor of the refined structure (69 Å$^2$).

Interestingly, SO$_4$ III is located at the interface between the basic patches of the CD22 d7 domain and the m971 HCDR2 and is stabilized by one hydrogen bond with the amide backbone of WH55 (Fig. 5). The B-factors of the sulfate ions range from 87 to 108 Å$^2$, only slightly higher than the overall B-factor of the refined structure (69 Å$^2$).

Interestingly, SO$_4$ III is located at the interface between the basic patches of the CD22 d7 domain and the m971 HCDR2 and is stabilized by one hydrogen bond with the amide backbone of WH55 (Fig. 5). The B-factors of the sulfate ions range from 87 to 108 Å$^2$, only slightly higher than the overall B-factor of the refined structure (69 Å$^2$).

Consensus motif XBBXBX (B being the basic amino acids arginine, lysine, or histidine and X being one of a range of aliphatic/aromatic amino acids) known to bind negatively charged heparin sulfate (17). The presence of putative heparin sulfate-binding motifs in CD22 appears conserved across mammals (Fig. S6) and suggests that heparin sulfate may play a role in CD22 signal transduction and/or in protein–protein interactions. To probe the ability of the CD22 membrane-proximal region to bind negatively charged polysaccharides, we tested binding of CD22d6–d7 to glycosaminoglycan (GAG) of 14 to 16 kDa molecular weight. For this experiment, we mixed CD22 (CD22d6–d7 or CD22d1–d7 constructs) in the presence or absence of m971 Fab, with 10× molar excess of GAG and tested the complex formation by size-exclusion chromatography (Fig. 5). The shift of the elution peak to an earlier volume suggested complex formation between CD22 and GAG, consistent with the presence of a putative heparin sulfate-binding site. Moreover, binding to GAG did not alter the binding of m971 (Fig. 5), as would be expected from the crystal structure because the two sites are nonoverlapping.

**Discussion**

CD22, a surface membrane glycoprotein expressed on developing and mature human B cells, represents a validated
antigen for CAR-T cell immunotherapy against B-ALL (18, 19). Here, we have structurally delineated the epitope of m971 by cocrystallization of a truncated form of CD22 containing its two most membrane-proximal domains and m971 Fab. This structure revealed that m971 binds to the most membrane-proximal Ig-like domain (d7) in CD22. Our biophysical and structural data also indicate that the epitope of m971 does not include the N634-linked glycan. As opposed to m971, the therapeutic antibody epratuzumab showed glycan dependency for binding to CD22 ECD (11). This hindrance dependency of mAbs for binding to glycans on the surface of the glycoprotein is particularly relevant because variable glycoforms on...
Molecular details of CD22 recognition by mAb m971

Figure 6. Structural representation of CD22 and CD19 targets on the B cell surface. Model depicting the size difference of the extracellular domains of CD22 and CD19. The CD22 ECD map determined by electron microscopy (EMD-8705) (11) is shown as a gray surface, fitted with the crystal structure of CD22_d1-d7 in complex with epratuzumab Fab (PDB ID: 5VL3) (11) and CD22-d1-d7 in complex with m971 Fab. The crystal structure of the CD19 ECD in complex with B43 Fab (PDB ID: 6AL5) (41) is represented as a cartoon. The electron microscopy map and crystal structures were generated using UCSF Chimera. ECD, extracellular domain; Fab, fragment antigen-binding.

N-glycans, such as truncations or modified branching patterns, have been observed in cancer cells (20, 21). However, it is still unknown how the glycosylation patterns of CD22 vary among B cell-derived malignancies and patients.

For the efficacy of CAR-T cell immunotherapy, it has been shown that proximity of cell membranes at the immune synapse between the T cell and tumor cell can be an important factor (22–24). This principle is based on the kinetic segregation model for T-cell receptor signaling (25). For this reason, the size of the target antigen on the tumor cell can play an important role for CAR efficacy (26). In light of these findings, it is interesting to compare the size of the extracellular portion of CD22 and CD19, two major antigens targets on B cells for immunotherapy in B-ALL. While the ECD of CD19 is composed of a hybrid-type Ig-like domain extending around 60 Å, CD22 extends 300 Å with its seven Ig-like domains (d1–d7) (Fig. 6). As previously reported, targeting the membrane-proximal Ig-like domain on CD22 with m971-derived CAR-T cells showed comparable antileukemic activity to anti-CD19 CAR-T cells (10). Moreover, m971-derived CAR-T cell showed higher activity than anti-CD22 CAR-T cells of similar affinity targeting membrane-distal regions (9, 10). A similar epitope location dependency was reported for CAR-T cells against mesothelin (MSLN) (27). Indeed, CARs targeting the membrane-proximal region on MSLN showed increased cytotoxic and cytokine secretion compared with membrane-distal epitope-targeting CARs. As with anti-MSLN CARs, we cannot rule out the possibility that membrane-proximal regions on the targeted CD22 are structurally rigid and thus enable better signal transduction. In addition, the membrane-distal epitopes on CD22 may be participating in interactions with cis-ligands and trans-ligands, which might impede CAR binding. Although these examples across three antigens highlight the value of targeting membrane-proximal extracellular epitopes for CAR-T efficacy, further work will be required to determine whether these observations translate into a generalizable model that membrane proximal-targeting CARs are consistently better than membrane distal-targeting CARs.

Antigen-binding affinity should also be considered in the design of CAR-T cells (3, 28). Indeed, CAR-T cells possessing low micromolar affinity (1 μM) have been shown to be capable of lysing cells overexpressing target antigens while sparing those with much lower densities (29). On the other hand, early studies using human epidermal growth factor receptor 2-CAR-T cells with varying affinities demonstrated that the activation threshold of CAR-T cells is inversely correlated with the binding affinity (30). By functionally investigating the affinity of various mutants of m971 Fab designed based on our co-crystal structure, we developed a range of binding affinities for m971 variants toward CD22. In this case, the 5-fold gain in affinity for CD22 of YH52AR m971-derived CAR-T cells was not transduced in altered cell killing.

For the generation of more effective mAbs, it is relevant to understand the biological environment in which the target molecule is present. Antibodies should indeed recognize their epitopes in the context of their biological environments. For this reason, binding of mAbs to domains close to the cell surface can be influenced by the presence of phospholipids and glycolipids. Indeed, previously characterized mAbs interacting with membrane-proximal epitopes, such as the anti-HIV-1 envelope glycoprotein 41 broadly neutralizing antibodies 2F5 (31) and 4E10 (32), were found to directly interact with membrane lipid components. Despite the fact that m971 was selected against a recombinant CD22 by phage display (14, 33), the presence of sulfate ions near basic surface patches close to the base of the CD22–m971 complex raise the question of whether positively charged residues on HCDR2 are important for antigen-binding affinity (30). By functionally investigating the affinity and specificity of various mutants of m971 Fab designed based on our co-crystal structure, we developed a range of binding affinities for m971 variants toward CD22. In this case, the 5-fold gain in affinity for CD22 of YH52AR m971-derived CAR-T cells was not transduced in altered cell killing.

Experimental procedures

CD22_d6–d7 and CD22_d1–d7 construct design, expression, and purification

Full-length CD22 ECD (CD22_d1–d7; residues 20–687) was designed, expressed, and purified as previously described (11). The CD22_d6–d7 (residues 505–688) construct was generated from CD22_d1–d7 using In-Fusion HD Cloning Kit (Takara) following the manufacturer’s instructions. The construct was cloned into the pHLsec vector (34) using restriction enzymes AgeI and KpnI, such that a 6x His tag was added at the C terminus of the construct to facilitate affinity purification. CD22_d6–d7 was transiently transfected using the transfection reagent FectoPRO (Polyplus Transfection) in HEK 293 Gnt I−/− (HEK 293S; ATCC CRL-3022) suspension cells for protein expression. HEK 293S cells were incubated at 37 °C,
180 rpm, 8% CO₂ in a Multitron Pro shaker (Infors HT) for 6 to 7 days. After harvesting the cells by centrifugation, supernatants were retained and filtered using a 0.22 μm Steritop filter (EMD Millipore). Supernatants were passed through a HisTrap Ni-NTA column (GE Healthcare) at 4 ml min⁻¹. The column was washed with 20 mM Tris, pH 8.0, 150 mM NaCl, and 5 mM imidazole buffer before elution with an increasing gradient of imidazole (up to 500 mM). Fractions containing protein were pooled, concentrated, and separated on a Superdex 200 Increase size exclusion column (GE Healthcare) at 0.5 ml min⁻¹ in 20 mM Tris, pH 8.0, 150 mM NaCl buffer to achieve size homogeneity. To obtain deglycosylated samples, purified CD22d6--d7--m971 Fab complex was treated with the enzyme Endo H (New England Biolabs) for 1 h at 37 °C. The deglycosylated complex was purified further via a second Superdex 200 Increase size-exclusion column (GE Healthcare) at 0.5 ml min⁻¹ in 20 mM Tris, pH 8.0, and 150 mM NaCl buffer.

**Molecular details of CD22 recognition by mAb m971**

The m971 IgG construct was kindly provided by Dr Yan Feng. The heavy chain and light chain of m971 Fab were subcloned into the pHLsec vector (34) using In-Fusion HD Cloning Kit (Takara) following the manufacturer’s instructions. Point mutations S₁¹¹₁BQ, Y₁₅₂₁A₂R, Y₁₅₂₁A₂E, S₁₅₃₁A, or L₁¹¹₀₀Q were introduced by PCR using the QuikChange Site-Directed Mutagenesis protocol. The heavy chain and light chain of the m971 Fab were cotransfected in HEK 293S cells at a 1:1.5:1 ratio of CD22:HC:LC DNA and using FectoPRO (Polyplus Transfection). Cells were cotransfected at a cell density of 0.8 × 10⁶ cells ml⁻¹ and incubated at 37 °C, 125 rpm, 8% CO₂ in a Multitron Pro shaker (Infors HT) for 5 to 7 days. Cells were harvested, and supernatants retained and filtered with a 0.22 μm membrane (EMD Millipore). Supernatants were flowed through a KappaSelect affinity column (GE Healthcare) using an AKTA Start chromatography system (GE Healthcare) and eluted with 100 mM glycine, pH 2.2. Eluted fractions were immediately neutralized with 1 M Tris HCl, pH 9.0. Fractions containing protein were pooled and run through a desalting column to change the sample buffer into 20 mM sodium acetate, pH 5.6. Ion-exchange chromatography was performed using a Mono S column (GE Healthcare) and eluted with a potassium chloride gradient. Fractions were pooled, concentrated, and flowed on a Superdex 200 Increase gel filtration column (GE Healthcare) to obtain purified samples.

**CD22d6--d7 Fab complex expression and purification**

CD22d6--d7 was transiently cotransfected with the heavy chain and light chain of the m971 Fab into HEK 293S cells at a 1:1.5:1 ratio of CD22:HC:LC DNA and using FectoPRO (Polyplus Transfection). Cells were cotransfected at a cell density of 0.8 × 10⁶ cells ml⁻¹ and incubated at 37 °C, 125 rpm, 8% CO₂ in a Multitron Pro shaker (Infors HT) for 5 to 7 days. After harvesting the cells by centrifugation at 6371 g for 20 min, supernatants were retained and filtered using a 0.22 μm Steritop filter (EMD Millipore). Supernatants were passed through a HiTrap Ni-NTA column (GE Healthcare) at 4 ml min⁻¹. The column was washed with 20 mM Tris, pH 8.0, 150 mM NaCl, and 5 mM imidazole buffer before elution with an increasing gradient of imidazole (up to 500 mM). Fractions containing protein were pooled, concentrated, and separated on a Superdex 200 Increase size exclusion column (GE Healthcare) at 0.5 ml min⁻¹ in 20 mM Tris, pH 8.0, 150 mM NaCl buffer to achieve size homogeneity. To obtain deglycosylated samples, purified CD22d6--d7--m971 Fab complex was treated with the enzyme Endo H (New England Biolabs) for 1 h at 37 °C. The deglycosylated complex was purified further via a second Superdex 200 Increase size-exclusion column (GE Healthcare) at 0.5 ml min⁻¹ in 20 mM Tris, pH 8.0, and 150 mM NaCl buffer.

**CD22 and GAG complex formation**

CD22d1--d7 and CD22d6--d7 were mixed and incubated for 30 min on ice with 10x molar excess of heparin sodium salt GAG of 14 to 16 kDa molecular weight (Toronto Research Chemicals, H245800). Samples were run on a Superdex 200 Increase size exclusion column (GE Healthcare) at 0.5 ml min⁻¹ in 20 mM Tris, pH 8.0, and 150 mM NaCl buffer. Epratuzumab Fab was used as a control protein.

**Melting and aggregation temperature measurements**

The T_m and the T_onset were simultaneously assessed by monitoring the intrinsic fluorescence emission and SLS (266 nm) using a UNit instrument (Unchained Labs). The T_m was determined as the inflection point in the primary data plotted as a function of the temperature, and the T_onset was measured by determining the temperature at which the SLS signal reaches a threshold that is 10% of its maximum value. Thermal stability was analyzed using a temperature ramp from 20 to 85 °C using 1 °C increments, with an equilibration time of 60 s before each measurement. Samples were prepared at 1 mg ml⁻¹. Measurements were made in 100 mM Tris (pH 9.0), Hepes (pH 7.4), and sodium acetate (pH 5.6) buffers with 150 mM NaCl. Measurements were made in duplicates and averaged, and standard errors were calculated using GraphPad Prism v6.

**Bli**

The binding affinities of WT m971 Fab or m971 Fab mutants to different CD22 ECD (CD22d1, CD22d6, and CD22dN₆₃₄A) were measured by Bli using the Octet RED96 Bli system (Pall ForteBio). Ni-NTA biosensors were hydrated in 1x kinetics buffer (20 mM Tris, pH 7.4, 0.002% Tween, 0.01% BSA) and loaded with 25 ng μl⁻¹ of CD22d₁--d₇ for 60 s at 1000 rpm. Biosensors were then transferred into wells containing 1x kinetics buffer to baseline for 60 s before being transferred into wells containing a serial dilution of Fab starting at 200 nM and decreasing to 25 nM. The 180 s association phase was subsequently followed by a 180 s dissociation step in 1x kinetics. Analysis was performed using the Octet software, with a 1:1 fit model. All experiments were repeated in duplicates, values were averaged, and standard errors were calculated.

**m971 CAR-T cell production and cellular cytotoxicity assay**

m971 CAR-T cells were produced by lentiviral transduction of human Jurkat T cell lines. Lentivirus was packaged in HEK 293T cells by cotransfecting pLVX-ires-m971 CAR, pSpxA2, and pMD2.G plasmids. Virus was purified and concentrated by the Retro-X Concentrator (Takara, Clontech). Human Jurkat T cell lines were transduced by the spinoculation method.
Briefly, the virus was attached into RetroNectin (Takara, Clontech) coated non-tissue culture-treated 6-well plates by centrifugation at 2000g, 30 °C for 2 h. Then, the supernatant was aspirated and Jurkat T cells were added into plates by centrifugation at 100g at 30 °C for 10 min. To improve CAR expression, the next day, Jurkat T cells were incubated with Raji cells (10^4 cells) in triplicates with a E:T ratio of 10:1 for 24 h. Killing of Raji cells was detected by the Promega CytoTox-Glo Cytotoxicity Assay (Cat. No. G9290) with the following formula: lysis% = 100 × (RLUE+T-RLUE-)/(RLU_{max}-RLU_{T}), wherein RLUE_{E+T} refers to the luminescence intensity of wells with effector cell incubation with target cells and RLU_{E} and RLU_{T} are for spontaneous signals for effector cells and target cells alone.

**Crystallization and X-ray diffraction**

To obtain crystals of m971, the purified Fab was mixed with 2 to 5× molar excess of anti-kappa V_{H} domain (catalog number: 1033270500, BAC BV (Thermo Fisher Scientific)) as described previously (15) and run on a gel filtration chromatography. The purified m971 Fab-V_{H} complex was concentrated to 9 mg ml^{-1} in 20 mM sodium acetate, pH 5.6. Crystals of the m971 Fab-V_{H} complex were obtained by sitting-drop vapor diffusion at 20 °C in 0.2 M lithium acetate, and 20% (w/v) PEG3550 in 96-well plates after mixing 0.15 μl of protein and 0.15 μl of solution using an Oryx4 crystallization robot (Douglas Instruments). Crystals were cryoprotected by soaking them in the mother liquor solution containing 20% glycerol and flash-cooled in liquid nitrogen. X-ray diffraction data were collected at the 08ID synchrotron beamline at the Canadian Light Source. The dataset of the m971 Fab-V_{H} complex was processed in space group P3_1 using XDS (35). The structure was solved by molecular replacement in Phaser using the variable and constant domains of Fab fragments from our internal database as search models and refined by manual building in Coot (36) and using phenix.refine (37).

The purified CD22_{d6-d7-m971} Fab complex was concentrated to 12 mg ml^{-1} in 20 mM Tris, pH 8.0, and 150 mM NaCl. Crystals of the CD22_{d6-d7-m971} Fab complex were obtained by sitting-drop vapor diffusion at 20 °C in 2 M ammonium sulfate and 0.1 M Hepes, pH 7.5, in 96-well plates after mixing 0.15 μl of protein and 0.15 μl of solution using an Oryx4 crystallization robot (Douglas Instruments). Crystals were cryoprotected by soaking them in the mother liquor solution containing 20% glycerol and flash-cooled in liquid nitrogen. X-ray diffraction data were collected at the 08ID synchrotron beamline at the Canadian Light Source. The dataset of the CD22_{d6-d7-m971} Fab complex was processed in space group I222 using XDS (35). The structure was solved by molecular replacement in Phaser using the structure of unliganded m971 Fab as a starting model and refined by manual building in Coot (36) and using phenix.refine (37). Data collection and refinement statistics are reported in Table 1. All software programs were accessed through SBGrid (38).

**Data availability**

The crystal structures have been deposited in the Protein Data Bank, www.rcsb.org (PDB ID: 7O4Y and 7O52).

**Supporting information**—This article contains supporting information (39, 40, 42).

**Acknowledgments**—X-ray diffraction experiments described in this article were performed using beamline 08ID at the Canadian Light Source, which is supported by the Canada Foundation for Innovation, Natural Sciences and Engineering Research Council of Canada, the University of Saskatchewan, the Government of Saskatchewan, Western Economic Diversification Canada, the National Research Council Canada, and the Canadian Institutes of Health Research.

**Author contributions**—J. E.-O., X. L., I. K., W. L., Y. F., D. S. D., and J.-P. J. conceptualization; J. E.-O., D. S. D., and J.-P. J. supervision; J. E.-O., T. S., I. K., and J.-P. J. funding acquisition; J. E.-O., T. S., and J.-P. J. validation; J. E.-O., X. L., T. S., I. K., D. B., H. C., and Y. F. investigation; J. E.-O., T. S., and I. K. visualization; J. E.-O., X. L., T. S., I. K., D. B., H. C., Y. F., and J.-P. J. methodology; J. E.-O., X. L., D. S. D., and J.-P. J. writing—original draft; J. E.-O. project administration; J. E.-O., X. L., T. S., W. L., Y. F., D. S. D., and J.-P. J. writing—review and editing.

**Funding and additional information**—This work was supported by operating grant PJT-148811 (to J.-P. J.) from the Canadian Institutes of Health Research, the CIFAR Azrieli Global Scholar program (to J.-P. J.), the Ontario Early Researcher Award program (to J.-P. J.), and the Canada Research Chairs program (to J.-P. J.). J. E.-O. was supported by Banting Postdoctoral Fellowship BPF-144483 from the Canadian Institutes of Health Research. T. S. is a recipient of a Vanier Canada Graduate Scholarship.

**Conflict of interest**—The authors declare that they have no conflicts of interest with the contents of this article.

**Abbreviations**—The abbreviations used are: B-ALL, B-cell acute lymphoblastic leukemia; BLI, biolayer interferometry; CARs, chimeric antigen receptors; CAR-T cell, chimeric antigen receptor T cell; CD22, cluster of differentiation-22; ECD, extracellular domain; Fab, fragment antigen-binding; GAG, glycosaminoglycan; HCDRs, heavy-chain complementarity-determining regions; HEK 293S, HEK 293 GnT I−/−; Ig, immunoglobulin; ITIMs, intracellular tyrosine-based inhibitory motifs; MSLN, mesothelin; Siglec, sialic acid-binding immunoglobulin-like lectin; SLS, static light scattering; T_{melting}; melten temperature; T_{onset}, onset aggregation temperature.

**References**

1. Labanieh, L., Majzner, R. G., and Mackall, C. L. (2018) Programming CAR-T cells to kill cancer. Nat. Biomed. Eng. 2, 377–391
2. Harris, D. T., and Kranz, D. M. (2016) Adoptive T cell therapies: A comparison of T cell receptors and chimeric antigen receptors. Trends Pharmacol. Sci. 37, 220–230
3. Srivastava, S., and Riddell, S. R. (2015) Engineering CAR-T cells: Design concepts. Trends Immunol. 36, 494–502
4. Zhang, J., Li, J., Ma, Q., Yang, H., Signorovitch, J., and Wu, E. (2020) A review of two regulatory approved anti-CD19 CAR T-cell therapies in diffuse large B-cell lymphoma: Why are indirect treatment comparisons not feasible? Adv. Ther. 37, 3040–3058

---

**Molecular details of CD22 recognition by mAb m971**

J. Biol. Chem. (2021) 297(2) 100966

---

---
Molecular details of CD22 recognition by mAb m971

5. Gardner, R., Wu, D., Cherian, S., Fang, M., Hanafi, L.-A., Finney, O., Smithers, H., Jensen, M. C., Riddell, S. R., Maloney, D. G., and Turtle, C. J. (2016) Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. *Blood* **127**, 2406–2410

6. Brentjens, R. J., Rivière, I., Park, I. H., Davila, M. L., Wang, X., Steffans, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., Olszewska, M., Bernal, Y., Pugram, H., Przybylowiski, M., Hollyman, D., et al. (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. *Blood* **118**, 4817–4828

7. Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Steffans, J., Taylor, C., Olszewska, M., Borquez-Ojeda, O., Qu, J., Wasielewska, T., He, Q., Bernal, Y., et al. (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. *Sci. Transl. Med.* **5**, 177ra38

8. Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., Mahnke, Y. D., Melenhorst, J. J., Rheingold, S. R., Shen, A., Teachey, D. T., et al. (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. *N. Engl. J. Med.* **371**, 1507–1517

9. Fry, T. J., Shah, N. N., Orentas, R. J., Stetler-stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P., Martin, S., Delbrook, C., Yates, B., Shalabi, H., Fountaine, T. J., Shern, J. F., Majzner, R. G., Stroncek, D. F., et al. (2018) CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted. *Nat. Med.* **24**, 20–28

10. Haso, W., Lee, D. W., Shah, N. N., Stetler-stevenson, M., Yuan, C. M., Pastan, I. H., Dimitrov, D. S., Morgan, R. A., FitzGerald, D. J., Barrett, D. M., Wayne, A. S., Mackall, C. L., and Orentas, R. J. (2013) Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. *Blood* **121**, 1165–1174

11. Ereño-Orbea, J., Sicard, T., Cui, H., Mazhab-Jafari, M. T., Benlekbir, S., Guarné, A., Rubinstein, J. L., and Julien, J. P. (2017) Molecular basis of human CD22 function and therapeutic targeting. *Nat. Commun.* **8**, 764

12. Walker, J. A., and Smith, K. G. C. (2008) CD22: An inhibitory enigma. *Immunochemistry* **123**, 314–325

13. Gasparini, F., Feest, C., Bruckbauer, A., Mattlka, P. P., Müller, I., Nitschke, L., Bray, D., and Batista, F. D. (2015) Nanoscale organization and dynamics of the siglec CD22 cooperate with the cytokines to restrain BCR signalling. *EMBO J.* **35**, 1–23

14. Xiao, X., Ho, M., Zhu, Z., Pastan, I., and Dimitrov, D. S. (2009) Identification and characterization of fully human anti-CD22 monoclonal antibodies. *MAbs* **1**, 297–303

15. Ereño-Orbea, J., Sicard, T., Cui, H., Carson, J., Hermans, P., and Julien, J.-P. (2018) Structural basis of enhanced crystallizability induced by a molecular chaperone for antibody antigen-binding fragments. *J. Mol. Biol.* **430**, 322–336

16. Pronker, M. F., Lemstra, S., Snijder, J., Heck, A. J. R., Thies-Weesie, D. M. E., Pasterkamp, R. J., and Janssen, B. J. C. (2016) Structural basis of myelin-associated glycoprotein adhesion and signalling. *Nat. Commun.* **7**, 13584

17. Hileman, R. E., Fromm, J. R., Weiler, J. M., and Linhardt, R. J. (1998) Molecular details of CD22 recognition by mAb m971. *J. Immunol.* **161**, 2507–2514

18. Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., Mahnke, Y. D., Melenhorst, J. J., Rheingold, S. R., Shen, A., Teachey, D. T., et al. (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. *N. Engl. J. Med.* **371**, 1507–1517

19. Fry, T. J., Shah, N. N., Orentas, R. J., Stetler-stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P., Martin, S., Delbrook, C., Yates, B., Shalabi, H., Fountaine, T. J., Shern, J. F., Majzner, R. G., Stroncek, D. F., et al. (2018) CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted. *Nat. Med.* **24**, 20–28

20. Haso, W., Lee, D. W., Shah, N. N., Stetler-stevenson, M., Yuan, C. M., Pastan, I. H., Dimitrov, D. S., Morgan, R. A., FitzGerald, D. J., Barrett, D. M., Wayne, A. S., Mackall, C. L., and Orentas, R. J. (2013) Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. *Blood* **121**, 1165–1174

21. Ereño-Orbea, J., Sicard, T., Cui, H., Mazhab-Jafari, M. T., Benlekbir, S., Guarné, A., Rubinstein, J. L., and Julien, J. P. (2017) Molecular basis of human CD22 function and therapeutic targeting. *Nat. Commun.* **8**, 764

22. Walker, J. A., and Smith, K. G. C. (2008) CD22: An inhibitory enigma. *Immunochemistry* **123**, 314–325

23. Aricescu, A. R., Lu, W., and Jones, E. Y. (2006) A time- and cost-efficient system for high-level protein production in mammalian cells. *Acta Crystallogr. D Biol. Crystallogr.* **62**, 1243–1250

24. Kabsch, W. (2010) XDS. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 125–132

25. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 486–501

26. Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., et al. (2010) PHENIX: A comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 213–221

27. Morin, A., Eisenbraun, B., Key, J., Sanschagrin, P. C., Timony, M. A., Ottaviano, M., and Sliz, P. (2013) Collaboration gets the most out of software. *Elife* **2**, e01456

28. Unni, S., Huang, Y., Hanson, R. M., Tobias, M., Krishnan, S., Li, W. W., Nielsen, J. E., and Baker, N. A. (2011) Web servers and services for electrostatics calculations with APBS and PDB2PQR. *J. Comput. Chem.* **32**, 1488–1491

29. Schrödinger, L. (2015) The PyMol Molecular Graphics System, Version 2.0. Schrödinger, LLC, New York, NY

30. Teplyakov, A., Obmolova, G., Luo, J., and Gildil, G. L. (2018) Crystal structure of B-cell co-receptor CD19 in complex with antibody B43 reveals an unexpected fold. *Proteins* **86**, 495–500

31. Sievers, F., and Higgins, D. (2014) Clustal omega, accurate alignment of very large numbers of sequence. *Methods Mol. Biol.* **1079**, 105–116